


New Approaches to Target Bacterial Infections

A multinational pharmaceutical company is seeking **new antibiotic compounds** and adjuvants **with antibacterial or antifungal activity** or repositioned or repurposed molecules as novel therapeutics targeting multidrug-resistant bacterial pathogens. The focus is on agents that demonstrated antibacterial effects incidentally during development for unrelated indications.



Approaches of Interest:

- **Repurposing** non-antibiotic drugs
- There is significant interest in clinical indications associated with **ESKAPE pathogens** as well as those caused by emerging pathogens such as ***Candida glabrata*, *Candida auris*, and *Aspergillus fumigatus***
- **Combination therapies** that overcome adverse effects of traditional antibiotics are preferred
- Drugs that have advantages over traditional antibiotics specifically in **resistance avoidance and safety profile**

Developmental Stages of Interest:

- Opportunities from preclinical research to registration are in scope
 - For preclinical research, small molecules will be prioritised. Peptides are of limited interest, while biologics and non-molecular approaches are out of scope
 - For research in clinical trials and beyond, all modalities are in scope

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Opportunities sought

-  Technologies
-  Academics and expertise
-  Centres of excellence
-  Research projects
-  Spinout companies
-  Biotech assets

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **18th November 2025 - 11:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk